Celgene (NASDAQ:CELG) fights the sell-off

This CEO performance shows that CELG has my sort of management team. That's in contrast to the CEO of a different biotech company with a similar long-term stock chart who closed the Q4 conference call by responding to a question about when growth would resume beyond 2017 this way:

But at this point, I'm not going to give you a point in time when that's going to happen.

That inspired no confidence amongst investors.

READ FULL ARTICLE HERE